Opinion of the CVMP on the establishment of maximum residue limits: Praziquantel

Human medicines European public assessment report (EPAR): Sildenafil Actavis, sildenafil, Erectile Dysfunction, Date of authorisation: 10/12/2009, Revision: 17, Status: Authorised

Guide to information on human medicines evaluated by European Medicines Agency: what the Agency publishes and when

Addendum to EMA/CHMP/CVMP/QWP/17760/2009 Rev 3: Defining the Scope of an NIRS Procedure

Opinion/decision on a Paediatric investigation plan (PIP): Lacutamab, decision type: , therapeutic area: , PIP number: P/0483/2022

Opinion/decision on a Paediatric investigation plan (PIP): 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one, decision type: , therapeutic area: , PIP number: P/0493/2022

Opinion/decision on a Paediatric investigation plan (PIP): Namilumab, decision type: , therapeutic area: , PIP number: P/0471/2022

Opinion/decision on a Paediatric investigation plan (PIP): Tigulixostat, decision type: , therapeutic area: , PIP number: P/0511/2022

Human medicines European public assessment report (EPAR): Cresemba, isavuconazole, Aspergillosis, Date of authorisation: 15/10/2015, Revision: 17, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq,Upadacitinib (ABT-494), decision type: , therapeutic area: , PIP number: P/0514/2022